Amenorrhea Treatments

Find Amenorrhea Treatments

Generic Name

MedroxyPROGESTERone Acetate

Brand Names

Prempro, Depo-Provera, MedroxyPROGESTERone, Provera, Depo-SubQ Provera, Premphase

FDA approval date: June 03, 1959

Classification: Progestin

Form: Injection, Tablet, Kit

What is Prempro (MedroxyPROGESTERone Acetate)?

Medroxyprogesterone Acetate Tablets USP are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. They are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Study Phase: Not Applicable

Summary: The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) and virally suppressed, leading up to a hybrid type I effectiveness-implementation trial randomizing individual AGYWLHIV to receive long-acting (LA) injectable cab...

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live lon...

A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months

Enrollment Status: Recruiting

Publish Date: April 01, 2026

Intervention Type: Drug, Combination product

Study Phase: Phase 3

Summary: Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH). Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If thi...

View All Clinical Trials